Imipramine compared to conservative treatment of urinary incontinence in women urgency.

Imipramine versus conservative treatment in women with Overactive Bladder Syndrome.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

REBEC

Registry ID

RBR-64wczh

Enrollment

Unknown

Registered

2012-02-01

Start date

2010-05-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urgency Urinary Incontinence Overactive Bladder Syndrome Detrusor Instability

Interventions

Application in both groups of Quality of Life Questionnaire and the Questionnaire for Urinary Incontinence. Realization of perineal exercises and bladder retraining for patients selected for randomiza

drug

device

D03.494.240.485

V02.575.700

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Women older than 18 years, complaining of urge incontinence or mixed (with a major component of emergency)

Exclusion criteria

Exclusion criteria: Pelvic surgery for correction of urinary incontinence less than two years, presence of vaginal or urinary infection, can not understand or sign the informed consent; not understand or are unable to perform the proposed treatment, pregnancy or the postpartum period including the period of six months after delivery; intolerance to the use of imipramine; Urinary Incontinence Mixed Incontinence pure or predominant component of the effort, heart disease, severe liver disease, severe kidney disease with loss of renal function, hyperthyroidism, acute angle glaucoma, epilepsy disease; Parkinson's disease, uncontrolled hypertension, patients with a history of alcohol or drugs.

Design outcomes

Primary

Measure	Time frame
Improvement in urinary incontinence obtained by comparing the scores of questionnaires in General Health Perception, Incontinence Impact and Final score in the Quality of Life Questionnaire score and the final Questinário Incontinence Severity Index. Urodynamic parameters by comparing the amount of urine loss and the presence of non-inhibited contractions.	—

Secondary

Measure	Time frame
Validate the use of imipramine as safe and effective option for patients with overactive bladder syndrome. ;Verify the occurrence and frequency of adverse effects from the use of imipramine.	—

Countries

Brazil

Contacts

Public ContactRenata Burmann

Hospital de Clínicas de Porto Alegrte - HCPA

renatah_puc@yahoo.com.br51.3359.8000

Outcome results

None listed

Source: REBEC (via WHO ICTRP)